Afatinib-Induced Acute Fatal Pneumonitis in Metastatic Lung Adenocarcinoma.
10.4082/kjfm.2016.37.6.351
- Author:
Sang Hoon YOO
1
;
Jin Ah RYU
;
Seo Ree KIM
;
Su Yun OH
;
Gu Sung JUNG
;
Dong Jae LEE
;
Bong Gyu KWAK
;
Yu Hyun NAM
;
Kyung Hyun KIM
;
Young Jun YANG
Author Information
1. Department of Internal Medicine, Daejeon St. Mary's Hospital, The Catholic University of Korea College of Medicine, Daejeon, Korea. yyj7009@daum.net
- Publication Type:Case Report
- Keywords:
Afatinib;
Acute Fatal Pneumonitis;
Metastatic Lung Adenocarcinoma
- MeSH:
Acne Vulgaris;
Adenocarcinoma*;
Appetite;
Clinical Study;
Diarrhea;
Drug Resistance;
Erlotinib Hydrochloride;
Exanthema;
Humans;
Lung*;
Nausea;
Pneumonia*;
Protein-Tyrosine Kinases;
Pruritus;
Receptor, Epidermal Growth Factor;
Receptors, Vascular Endothelial Growth Factor;
Stomatitis;
Treatment Outcome
- From:Korean Journal of Family Medicine
2016;37(6):351-355
- CountryRepublic of Korea
- Language:English
-
Abstract:
Afatinib is an oral tyrosine kinase inhibitor (TKI) that inhibit Endothelial Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and HER4. The common side effects of EGFR TKI are rash, acne, diarrhea, stomatitis, pruritus, nausea, and loss of appetite. Drug induced pneumonitis is the less common adverse effects of EGFR TKI. Afatinib, 2nd generation EGFR TKI is anticipated to overcome drug resistance from 1st generation EGFR TKI according to preclinical study, and several studies are being conducted to compare clinical efficacy between 1st and 2nd EGFR TKI. Several cases of rug induced acute fatal pneumonitis were reported after use of erlotinib or gefitinib. However, a case of acute fatal pneumonitis associated with afatinib was note reported except drug induced pneumonitis in other clinical study. Here, we present a cases of acute severe pneumonitis related with afatinib in metastatic lung adenocarcinoma with literature review.
